Carret Asset Management LLC Invests $271,000 in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Carret Asset Management LLC acquired a new stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 36,140 shares of the company's stock, valued at approximately $271,000. Carret Asset Management LLC owned about 0.07% of Zevra Therapeutics as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ZVRA. BNP Paribas Financial Markets acquired a new stake in Zevra Therapeutics during the 4th quarter valued at $53,000. GAMMA Investing LLC raised its position in Zevra Therapeutics by 20,564.1% in the first quarter. GAMMA Investing LLC now owns 8,059 shares of the company's stock valued at $60,000 after purchasing an additional 8,020 shares during the period. Squarepoint Ops LLC raised its position in Zevra Therapeutics by 36.1% in the fourth quarter. Squarepoint Ops LLC now owns 16,534 shares of the company's stock valued at $138,000 after purchasing an additional 4,384 shares during the period. ProShare Advisors LLC purchased a new position in Zevra Therapeutics in the fourth quarter valued at about $145,000. Finally, Invesco Ltd. grew its stake in shares of Zevra Therapeutics by 19.6% during the fourth quarter. Invesco Ltd. now owns 18,384 shares of the company's stock valued at $153,000 after acquiring an additional 3,007 shares in the last quarter. 35.03% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Canaccord Genuity Group boosted their price objective on Zevra Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a report on Thursday, March 13th. Wall Street Zen upgraded Zevra Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Guggenheim boosted their price objective on Zevra Therapeutics from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, March 13th. JMP Securities set a $18.00 target price on Zevra Therapeutics in a report on Wednesday, March 12th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price target on shares of Zevra Therapeutics in a report on Thursday, March 13th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $22.29.

Zevra Therapeutics Trading Down 0.3%

ZVRA traded down $0.03 during mid-day trading on Friday, hitting $9.04. The stock had a trading volume of 559,464 shares, compared to its average volume of 671,228. The stock's fifty day simple moving average is $8.20 and its 200-day simple moving average is $8.06. The company has a debt-to-equity ratio of 1.46, a current ratio of 3.02 and a quick ratio of 2.93. The firm has a market capitalization of $494.31 million, a price-to-earnings ratio of -4.76 and a beta of 2.01. Zevra Therapeutics, Inc. has a 1-year low of $4.20 and a 1-year high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.15. Zevra Therapeutics had a negative net margin of 226.78% and a negative return on equity of 201.05%. The firm had revenue of $20.40 million for the quarter, compared to analyst estimates of $16.96 million. During the same period in the previous year, the business earned ($0.40) EPS. As a group, research analysts forecast that Zevra Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.